Richard Klinghoffer, Ph.D.

Richard Klinghoffer brings 20 years of research, drug development and team leadership experience to Presage. His team established the Presage platform, CIVO™, which enables multiplexed drug efficacy studies in both in vivo preclinical models of cancer and the human oncology clinic. Before joining Presage, Dr. Klinghoffer worked in both small biotech and large pharma settings, most recently at Merck’s Rosetta Inpharmatics. At Rosetta, he led a team of scientists focused on identifying and validating cancer targets and predictive biomarkers of novel chemotherapeutics for Merck’s Oncology Franchise. Dr. Klinghoffer earned his Ph.D. from the University of Colorado Health Sciences Center and was a Special Fellow of the Leukemia and Lymphoma Society as a Postdoctoral Fellow at the Fred Hutchinson Cancer Research Center.